Table 2.

Phase I trials

Phase INo. patientsDrug
Mixed (cytotoxic + targeted)11DVG, TTV, TAS-106/CBDCA, AZA/VPA/CBDCA, DBT, XL-147/CBDCA/paclitaxel, CBDCA/paclitaxel/temsirolimus
Multityrosine kinase inhibitor7R04612910, tipifarnib/sorafenib, BMS-690514, BAY73-4506
Microtubule inhibitors6ANG-1005, MPC6827, MST-997
mTOR inhibitor6BEV/temsirolimus
Proteasome inhibitor6NPI, bortezomib/BEV
Antiangiogenics4BEV/VPA, BEV/AZD2171, PX-478
Cytotoxics3PBI-05204, EZN-2208
Hypomethylating agents3Azacytidine/VPA, decitabine
MEK inhibitor3AZD8330
PI3K inhibitor2PX-866, XL-184
Cell cycle2R04584820
HDAC inhibitors1PX-101
HSP90 inhibitors1BIIB-028
IGF-IR1R0485696
Organic arsenic1ZIO-101
Proapoptotic1AMG-655
Farnesyl transferase inhibitor1FTS
IFN based1Immunologic
Src inhibitor1Dasatinib
Total61

Abbreviations: BEV, bevacizumab; DBT, Doxil, bevacizumab, temsirolimus; DVG, Doxil, Velcade, gemcitabine; HDAC, histone deacetylase; HSP90, heat shock proteins; IGF-IR, insulin-like growth factor-I receptor; TTV, topotecan, Torisel, Velcade; VPA, valproic acid; PI3K, phosphatidylinositol 3-kinase; MEK, mitogen-activated protein/extracellular signal-regulated kinase kinase.